AVROBIO Future Growth
Future criteria checks 1/6
AVROBIO is forecast to grow earnings at 8.4% per annum. EPS is expected to grow by 8.5% per annum.
Key information
8.4%
Earnings growth rate
8.5%
EPS growth rate
Biotechs earnings growth | 24.0% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 15 Mar 2024 |
Recent future growth updates
Recent updates
Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK
Oct 18Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status
Sep 20AVROBIO granted FDA’s orphan drug designation for metabolic disorder therapy
Jul 13Here's Why We're Watching AVROBIO's (NASDAQ:AVRO) Cash Burn Situation
Nov 13We're Keeping An Eye On AVROBIO's (NASDAQ:AVRO) Cash Burn Rate
Aug 10AVROBIO: Fabrazyme's Full Approval Changes Things
May 05Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation
Mar 08AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise
Dec 25We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth
Nov 23AVROBIO readies $75M equity offering
Nov 19AVROBIO EPS misses by $0.19
Nov 05Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | -1 | N/A | N/A | 2 |
12/31/2025 | N/A | -47 | N/A | N/A | 3 |
12/31/2024 | N/A | -77 | N/A | N/A | 3 |
12/31/2023 | N/A | 12 | -63 | -63 | N/A |
9/30/2023 | N/A | -4 | -79 | -79 | N/A |
6/30/2023 | N/A | -5 | -75 | -75 | N/A |
3/31/2023 | N/A | -101 | -90 | -89 | N/A |
12/31/2022 | N/A | -106 | -97 | -97 | N/A |
9/30/2022 | N/A | -109 | -101 | -99 | N/A |
6/30/2022 | N/A | -119 | -109 | -108 | N/A |
3/31/2022 | N/A | -122 | -101 | -99 | N/A |
12/31/2021 | N/A | -119 | -100 | -98 | N/A |
9/30/2021 | N/A | -119 | -104 | -103 | N/A |
6/30/2021 | N/A | -123 | -104 | -103 | N/A |
3/31/2021 | N/A | -121 | -104 | -104 | N/A |
12/31/2020 | N/A | -120 | -100 | -99 | N/A |
9/30/2020 | N/A | -114 | -89 | -87 | N/A |
6/30/2020 | N/A | -95 | -77 | -75 | N/A |
3/31/2020 | N/A | -82 | -74 | -72 | N/A |
12/31/2019 | N/A | -73 | -69 | -68 | N/A |
9/30/2019 | N/A | -66 | -62 | -61 | N/A |
6/30/2019 | N/A | -61 | -61 | -59 | N/A |
3/31/2019 | N/A | -55 | -51 | -49 | N/A |
12/31/2018 | N/A | -49 | -39 | -38 | N/A |
9/30/2018 | N/A | -40 | -36 | -35 | N/A |
6/30/2018 | N/A | -35 | -27 | -26 | N/A |
3/31/2018 | N/A | -27 | -21 | -20 | N/A |
12/31/2017 | N/A | -19 | -17 | -16 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AVRO's forecast earnings growth (8.4% per year) is above the savings rate (2.4%).
Earnings vs Market: AVRO's earnings (8.4% per year) are forecast to grow slower than the US market (14.1% per year).
High Growth Earnings: AVRO's earnings are forecast to grow, but not significantly.
Revenue vs Market: Insufficient data to determine if AVRO's revenue is forecast to grow faster than the US market.
High Growth Revenue: AVRO is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AVRO's Return on Equity is forecast to be high in 3 years time